PERRIGO CO. news, videos and press releases
For more news please use our advanced search feature.
PERRIGO CO. - More news...
PERRIGO CO. - More news...
- Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations
- Perrigo Announces Quarterly Dividend
- Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
- Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024
- Opill and WNBA Team Up for Groundbreaking Partnership
- Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States
- Perrigo to Attend UBS Global Consumer and Retail Conference
- Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program
- Perrigo Increases its Quarterly Dividend
- Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024
- Perrigo Announces Early Results of Cash Tender Offer for Notes
- Perrigo Announces Cash Tender Offer for Notes
- Perrigo Reports Third Quarter Fiscal Year 2023 Financial Results From Continuing Operations
- Perrigo Announces Quarterly Dividend
- Perrigo to Attend Upcoming Consumer Investor Conferences
- Perrigo to Release Third Quarter 2023 Financial Results on November 7, 2023
- Perrigo Announces Leadership Update
- Perrigo to Attend Upcoming Consumer Investor Conferences
- Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations
- PERRIGO ANNOUNCES QUARTERLY DIVIDEND
- Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference
- Perrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive
- Perrigo Appoints Patrick Lockwood-Taylor as President and CEO
- FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use
- Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations
- Perrigo Announces Chief Executive Officer Retirement and Succession Plan
- PERRIGO ANNOUNCES QUARTERLY DIVIDEND
- Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023
- Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill® Daily Oral Contraceptive for OTC Use
- Perrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference
